XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 3 - Allocation of Consideration Transferred (Details) - Protagenic Therapeutics Inc [Member]
Feb. 12, 2016
USD ($)
Common Stock [Member]  
Atrinsic 400,000,000 shares Common stock, as converted to 25,867 shares $ 32,334
Preferred Stock [Member] | Series B Preferred Stock [Member]  
Atrinsic 400,000,000 shares Common stock, as converted to 25,867 shares 371,835
Total value of shares issued to Atrinsic on Merger date 404,169
Goodwill 404,169
Net value of consideration $ 0